Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancerChristopher G. Willett, Jeffrey W. Clark, David P. Ryan et al.|Nature Medicine|2004Cited by 2k
Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II StudyChristopher G. Willett, Dan G. Duda, Emmanuelle di Tomaso et al.|Journal of Clinical Oncology|2009Cited by 507
Founder and Recurrent CDH1 Mutations in Families With Hereditary Diffuse Gastric CancerPardeep Kaurah, David G. Huntsman, Andrée MacMillan et al.|JAMA|2007Cited by 455
Surrogate Markers for Antiangiogenic Therapy and Dose-Limiting Toxicities for Bevacizumab With Radiation and Chemotherapy: Continued Experience of a Phase I Trial in Rectal Cancer PatientsChristopher G. Willett, Gregory Y. Lauwers, Yves Boucher et al.|Journal of Clinical Oncology|2005Cited by 419
Autoimmune Pancreatitis: A Systemic Immune Complex Mediated DiseaseVikram Deshpande, Gregory Y. Lauwers, Sonia L. Chicano et al.|The American Journal of Surgical Pathology|2006Cited by 318